Tactile Medical Q4 revenue up 21% to $103.6M; acquires LymphaTech for $6.8M

TACTILE SYSTEMS TECHNOLOGY INC

Q4 2025 revenue $103.6M (+21% YoY); net income $10.6M ($0.46 diluted EPS) vs $9.7M ($0.40) in Q4 2024.
Full year 2025 revenue $329.5M (+12% YoY); adjusted EBITDA $44.8M ($37.1M in 2024).
FY2026 guidance: revenue $357-365M (8-11% growth), adjusted EBITDA $49-51M.
Acquired LymphaTech for $6.8M upfront cash plus contingent milestones; adds 3D scanning for lymphedema.
Repaid $26.3M term loan; repurchased $26.5M stock at avg $12.36 per share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.